Candel Therapeutics (NASDAQ:CADL) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a report published on Monday morning,Benzinga reports. They currently have a $23.00 target price on the stock.

A number of other equities research analysts have also commented on CADL. Brookline Capital Management upgraded Candel Therapeutics to a “strong-buy” rating in a research report on Wednesday, July 9th. Bank of America lowered Candel Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $13.00 to $7.00 in a research report on Wednesday, September 3rd. Finally, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Candel Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.00.

Candel Therapeutics Trading Down 2.5%

NASDAQ CADL opened at $5.40 on Monday. The business’s 50-day moving average price is $5.75 and its two-hundred day moving average price is $5.63. Candel Therapeutics has a 12 month low of $3.79 and a 12 month high of $14.60. The firm has a market capitalization of $296.43 million, a PE ratio of -7.83 and a beta of -0.90. The company has a current ratio of 7.04, a quick ratio of 7.04 and a debt-to-equity ratio of 0.01.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. On average, analysts expect that Candel Therapeutics will post -1.47 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Halter Ferguson Financial Inc. raised its stake in Candel Therapeutics by 12.0% during the 2nd quarter. Halter Ferguson Financial Inc. now owns 776,516 shares of the company’s stock worth $3,929,000 after buying an additional 83,363 shares during the period. Acorn Capital Advisors LLC raised its stake in Candel Therapeutics by 11.0% during the 1st quarter. Acorn Capital Advisors LLC now owns 2,152,252 shares of the company’s stock worth $12,160,000 after buying an additional 212,608 shares during the period. Squarepoint Ops LLC raised its stake in Candel Therapeutics by 86.6% during the 4th quarter. Squarepoint Ops LLC now owns 19,311 shares of the company’s stock worth $168,000 after buying an additional 8,962 shares during the period. Nuveen LLC acquired a new position in Candel Therapeutics during the 1st quarter worth approximately $442,000. Finally, Janney Montgomery Scott LLC raised its stake in Candel Therapeutics by 104.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 21,090 shares of the company’s stock worth $119,000 after buying an additional 10,765 shares during the period. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.